Quick Takeaways
- JPMORGAN CHASE & CO filed SCHEDULE 13G/A for REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN).
- Disclosed ownership: 5.1%.
- Date of event: 31 Mar 2025.
JPMORGAN CHASE & CO - 31 Mar 2025 SCHEDULE 13G/A Report for REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN)
- Filing Manager
- JPMORGAN CHASE & CO
- Reporting Manager
- JPMORGAN CHASE & CO.
- Symbol
- REGN
- Shares outstanding
- 108,753,608 shares
- Disclosed Ownership
- 5,546,434 shares
- Ownership
- 5.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 22 Apr 2025, 12:01:04 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 05 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"JPMORGAN CHASE & CO disclosed 5.1% ownership in REGENERON PHARMACEUTICALS, INC. Common Stock - par value $.001 per share (REGN) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 22 Apr 2025, 12:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| JPMORGAN CHASE & CO. | 5.1% | 5,546,434 | 4,877,261 | 30,735 | Rachel Tsvaygoft | Vice President |